Merck announces EC approves SC administration of Keytruda for all adult indications approved in the European Union: Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...

Tumor infiltrating lymphocyte (TIL) therapy uses immune cells harvested directly from a patient’s tumor.

Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...

Shares in Kazia Therapeutics have risen more than 50 per cent after its drug candidate appeared to successfully treat a woman ...

Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.

Cancer treatment drug Pembroria, which has the same active ingredient as Keytruda but is cheaper, has been licensed for ...

The FDA has halted clinical testing of an Intellia Therapeutics gene-editing therapy following a report that a patient in a Phase 3 study was hospitalized with liver complications. Intellia said the ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

At the first interim efficacy analysis, results from the primary endpoint of EFS showed a 60% reduction in the risk of tumor recurrence, progression or death for patients treated with neoadjuvant and ...

Even after Merck & Co.’s Keytruda has climbed to the top of the industry’s sales charts and racked up dozens of FDA-approved indications, the drug is showing it still has unfinished business. In the ...

Keytruda Qlex must be administered by a health care provider. The Food and Drug Administration (FDA) has approved Keytruda Qlex ™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients aged 12 ...